Subscribe to our channel http://bit.ly/AJSubscribe'>http://bit.ly/AJSubscribe

Subscribe to our channel http://bit.ly/AJSubscribe'>http://bit.ly/AJSubscribe


Swiss drug maker Novartis has lost a battle in India's highest court to patent an updated version of its cancer drug Gilvec. The Supreme Court has dismissed the application, saying the new version was only slightly different from the old one. The landmark ruling sets a precedent covering patents on all existing drugs in India. Updating medicines to gain new patents is known as 'evergreening.' Novartis has declared the modification took years of research and makes the drug more effective, and the company has succesfully patented the new version in nearly 40 other countries.

At Al Jazeera English, we focus on people and events that affect people's lives. We bring topics to light that often go underreported, listening to all sides of the story and giving a 'voice to the voiceless.'
Reaching more than 270 million households in over 140 countries across the globe, our viewers trust Al Jazeera English to keep them informed, inspired, and entertained.
Our impartial, factbased reporting wins worldwide praise and respect. It is our unique brand of journalism that the world has come to rely on.
We are reshaping global media and constantly working to strengthen our reputation as one of the world's most respected news and current affairs channels.

Social Media links:

Facebook:   / aljazeera  
Instagram: https://instagram.com/aljazeera/?ref=...
Twitter:   / ajenglish  
Website: http://www.aljazeera.com/
google+: https://plus.google.com/+aljazeera/posts